What is the 13F Pro Quality Score for BCRX?

13F Pro ranks BIOCRYST PHARMACEUTICALS INC (BCRX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View BCRX's current score at https://13fpro.ai/research/BCRX (free sign-up required for the full ranking).

Where does 13F Pro source BCRX data?

All BIOCRYST PHARMACEUTICALS INC fundamentals and ownership data come directly from SEC EDGAR. BIOCRYST PHARMACEUTICALS INC files with the SEC under CIK 882796. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is BCRX in?

BIOCRYST PHARMACEUTICALS INC (BCRX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is BCRX research updated on 13F Pro?

BCRX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

BIOCRYST PHARMACEUTICALS INC(BCRX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 882796 BCRX stock profile & AI dashboard →

13F Pro Quality Score

37.2/100

Rank #2,063 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

89.7/100

Profitability

6.8/100

Balance Sheet

0.5/100

Earnings Quality

30.0/100

Free Cash Flow

30.4/100

Institutional Flow

95.6/100

Revenue Scale

40.5/100

Dilution Risk

17.2/100

BCRX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for BIOCRYST PHARMACEUTICALS INC (BCRX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BCRX at 37.2/100 on a 32-signal composite quality model, placing it at rank #2,063 of 2,879 stocks — the bottom half of the AI-ranked universe. BCRX scores in the top quartile across institutional flow (95.6), revenue growth (89.7). Areas of concern include balance sheet strength (0.5) and profitability (6.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 17.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), BIOCRYST PHARMACEUTICALS INC reports quarterly revenue of $156.4M, net income of $-721.8M, free cash flow of $-62.2M. Top institutional holders of BCRX by reported 13-F value include BlackRock,, RA CAPITAL MANAGEMENT, L.P., DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), based on the most recent SEC filings. BCRX trades on the Nasdaq exchange and files with the SEC under CIK 882796. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BCRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BIOCRYST PHARMACEUTICALS INC directly from SEC EDGAR. BIOCRYST PHARMACEUTICALS INC's 13F Pro composite quality score has ranged between 8 and 82 since 2026, currently 37.2 — an improving long-term trajectory across 36 quarterly and live scoring snapshots.

✦

Fun facts about BIOCRYST PHARMACEUTICALS INC

Quirks, history, and lore behind BCRX — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biopharmaceutical company · small-cap · listed on Nasdaq · headquartered in North Carolina.
2
The Numbers
Annual revenue in the low hundreds of millions of dollars, driven almost entirely by a single approved antiviral drug — a high-stakes bet on one molecule.
3
The History
Founded in the 1980s, the company spent decades as a clinical-stage also-ran before finally landing a commercial product — patience measured in generations of investors.
4
The Secret
Its specialty is rare and serious diseases, with a particular obsession with hereditary angioedema (HAE) — a condition so uncommon most doctors go a career without seeing a case.
5
The Lore
Its oral HAE therapy became the first pill approved to prevent HAE attacks, threatening to displace injectable rivals and setting off a patent-war frenzy in the rare-disease world.
6
The Giveaway
Ticker BCRX, maker of ORLADEYO (berotralstat) — the once-daily capsule that put a tiny Durham biotech on the map for HAE patients worldwide.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$156.4M

Net Income

Q1 2026

$-721.8M

Free Cash Flow

Q1 2026

$-62.2M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+94.1% YoY

$874.8MFY 2025

FY22 $270.8MFY23 $331.4MFY24 $450.7MFY25 $874.8M

Net Income

+396.9% YoY

$263.9MFY 2025

FY22 $-247.1MFY23 $-226.5MFY24 $-88.9MFY25 $263.9M

Operating Income

+13508.9% YoY

$341.0MFY 2025

FY22 $-148.4MFY23 $-103.7MFY24 $-2.5MFY25 $341.0M

EPS (Diluted)

+381.4% YoY

$1.21FY 2025

FY22 $-1.33FY23 $-1.18FY24 $-0.43FY25 $1.21

Total Assets

+4.8% YoY

$514.2MFY 2025

FY22 $550.0MFY23 $517.0MFY24 $490.4MFY25 $514.2M

Total Debt

-100.0% YoY

$0.00FY 2025

FY22 $231.6MFY23 $303.2MFY24 $314.9MFY25 $0.00

Op. Cash Flow

+767.8% YoY

$347.4MFY 2025

FY22 $-161.8MFY23 $-95.1MFY24 $-52.0MFY25 $347.4M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$874.8M +94.1%	$450.7M +36.0%	$331.4M +22.4%	$270.8M +72.3%	$157.2M +782.4%	$17.8M
Net Income	$263.9M +396.9%	$-88.9M +60.8%	$-226.5M +8.3%	$-247.1M -34.3%	$-184.1M -0.7%	$-182.8M
Operating Income	$341.0M +13508.9%	$-2.5M +97.5%	$-103.7M +30.1%	$-148.4M +16.5%	$-177.7M -1.7%	$-174.8M
EPS (Diluted)	$1.21 +381.4%	$-0.43 +63.6%	$-1.18 +11.3%	$-1.33 -29.1%	$-1.03 +5.5%	$-1.09
Total Assets	$514.2M +4.8%	$490.4M -5.1%	$517.0M -6.0%	$550.0M -6.5%	$588.2M +75.7%	$334.7M
Total Debt	$0.00 -100.0%	$314.9M +3.8%	$303.2M +30.9%	$231.6M -22.3%	$298.1M +143.2%	$122.6M
Operating Cash Flow	$347.4M +767.8%	$-52.0M +45.3%	$-95.1M +41.2%	$-161.8M -13.9%	$-142.2M -5.2%	$-135.1M

AI Insight: BCRX Financial Trends

BioCryst swung from $246M profit in Q4 2025 to $722M loss in Q1 2026 after exceptional Q4 performance and debt refinancing.

• Revenue surged from $132M in Q4 2024 to $407M in Q4 2025, then dropped to $156M in Q1 2026.

• Operating income turned positive reaching $30M in Q2-Q3 2025 and $260M in Q4 2025 before plunging to $-702M in Q1 2026.

• Total debt was eliminated in Q4 2025 but jumped to $395M in Q1 2026 while equity deficit widened to $554M.

⚠ Q4 2025 appears anomalous with 156% revenue spike and $260M operating income surge requiring explanation.

⚠ Operating cash flow turned sharply negative to $-62M in Q1 2026 after strong $292M in Q4 2025.

AI Insight: BCRX Ratio Trends

BioCryst achieved breakout profitability with operating margin soaring to 64.0% in Q4 2025 before collapsing to -43.1% in the TTM period ending Q1 2026.

• Operating margin surged from -3.4% in Q4 2024 to 64.0% in Q4 2025, marking a dramatic turnaround.

• Net profit margin turned positive, climbing from -20.4% in Q4 2024 to 60.5% in Q4 2025.

• Return on assets improved from -21.9% in Q4 2024 to positive territory through Q3 2025.

⚠ TTM operating margin crashed to -43.1% despite strong Q4 2025 performance, suggesting potential volatility.

⚠ Q1 2026 data is entirely missing, creating uncertainty about recent operational performance.

Get alerted when BCRX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for BIOCRYST PHARMACEUTICALS INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of BCRX

BlackRock, Inc.
$215.6M22,650,988 sh
RA CAPITAL MANAGEMENT, L.P.
$150.7M15,827,186 sh
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$143.2M15,038,000 sh
STATE STREET CORP
$116.2M12,208,360 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$107.0M11,244,625 sh
VANGUARD CAPITAL MANAGEMENT LLC
$106.0M11,135,762 sh
TCG Crossover Management, LLC
$104.9M11,020,968 sh
JANUS HENDERSON GROUP PLC
$84.9M8,908,506 sh
PERCEPTIVE ADVISORS LLC
$70.8M7,434,033 sh
Vestal Point Capital, LP
$66.9M7,025,000 sh

Fund	Value	Shares
BlackRock, Inc.	$215.6M	22,650,988
RA CAPITAL MANAGEMENT, L.P.	$150.7M	15,827,186
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	$143.2M	15,038,000
STATE STREET CORP	$116.2M	12,208,360
VANGUARD PORTFOLIO MANAGEMENT LLC	$107.0M	11,244,625
VANGUARD CAPITAL MANAGEMENT LLC	$106.0M	11,135,762
TCG Crossover Management, LLC	$104.9M	11,020,968
JANUS HENDERSON GROUP PLC	$84.9M	8,908,506
PERCEPTIVE ADVISORS LLC	$70.8M	7,434,033
Vestal Point Capital, LP	$66.9M	7,025,000

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put BCRX on your watchlist

Track score changes the day BIOCRYST PHARMACEUTICALS INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is BCRX a good stock to buy?

13F Pro's AI-powered analysis of BIOCRYST PHARMACEUTICALS INC (BCRX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BCRX are available on the BCRX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own BCRX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BCRX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of BIOCRYST PHARMACEUTICALS INC's investment landscape.